Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

NCT00520780 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT00520780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00520780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Lead sponsor
Vifor Pharma
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2007
Completion date
September 30, 2009
Enrollment
456 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

anaemia, chronic heart failure, iron deficiency, iron deficiency anemia